Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

Summary

This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.

Conditions

• Stage IV Esophageal Adenocarcinoma
• Stage IV Esophageal Squamous Cell Carcinoma
• Stage IV Gastric Cancer
• Stage IV Adenocarcinoma of the Gastroesophageal Junction
• Stage IVA Esophageal Adenocarcinoma
• Stage IVA Esophageal Squamous Cell Carcinoma
• Stage IVA Gastric Cancer
• Stage IVA Adenocarcinoma of the Gastroesophageal Junction
• Stage IVB Esophageal Adenocarcinoma
• Stage IVB Esophageal Squamous Cell Carcinoma
• Stage IVB Gastric Cancer
• Stage IVB Gastroesophageal Junction Adenocarcinoma
• Metastatic Anal Canal Carcinoma
• Metastatic Colorectal Carcinoma
• Metastatic Esophageal Carcinoma
• Metastatic Gastric Carcinoma
• Metastatic Gastroesophageal Junction Adenocarcinoma
• Metastatic Hepatocellular Carcinoma
• Metastatic Malignant Digestive System Neoplasm
• Metastatic Small Intestinal Carcinoma
• Pancreatobiliary Carcinoma
• Pathologic Stage IV Gastric Cancer AJCC v8
• Pathologic Stage IVA Esophageal Adenocarcinoma AJCC v8
• Pathologic Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
• Pathologic Stage IVB Esophageal Adenocarcinoma AJCC v8
• Pathologic Stage IVB Esophageal Squamous Cell Carcinoma AJCC v8
• Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
• Postneoadjuvant Therapy Stage IV Esophageal Squamous Cell Carcinoma AJCC v8
• Postneoadjuvant Therapy Stage IV Gastric Cancer AJCC v8
• Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8
• Postneoadjuvant Therapy Stage IVA Esophageal Adenocarcinoma AJCC v8
• Postneoadjuvant Therapy Stage IVA Esophageal Squamous Cell Carcinoma AJCC v8
• Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8
• Postneoadjuvant Therapy Stage IVB Esophageal Adenocarcinoma AJCC v8
• Postneoadjuvant Therapy Stage IVB Esophageal Squamous Cell Carcinoma AJCC V8
• Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8
• Stage IV Anal Cancer AJCC v8
• Stage IV Colorectal Cancer AJCC v8
• Stage IV Hepatocellular Carcinoma AJCC v8
• Stage IVA Colorectal Cancer AJCC v8
• Stage IVA Hepatocellular Carcinoma AJCC v8
• Stage IVB Colorectal Cancer AJCC v8
• Stage IVB Hepatocellular Carcinoma AJCC v8
• Stage IVC Colorectal Cancer AJCC v8

Interventions

RADIATION

Radiation Therapy (RT)

Undergo radiation therapy

Sponsors & Collaborators

• Varian Medical Systems

  collaborator INDUSTRY

• University of California, San Francisco

  lead OTHER

Principal Investigators

• Mary Feng, MD · University of California, San Francisco

Study Design

Allocation

NA

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2020-08-07

Primary Completion

2026-06-30

Completion

2028-04-30

FDA Device

Yes

Countries

• United States

Study Locations